The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
"New Age has reprocessed the existing 2D seismic data over the license during 2020, which has yielded a considerable improvement in resolution, and expects to have updated analysis and volumetrics available in January 2021, which will also be made available to potential farm-in partners. The Company will update the market further when it receives this analysis."
Above news likely due tomorrow or Friday
£20k buy at 0.5 yesterday, yours right now for 0.4
harmonic butterfly reversal on
https://twitter.com/alwayznow_/status/1354385126835294209?s=20
Lots of upside from here with some gaps to fill in the chart - https://twitter.com/Justsharesonaim/status/1354004376994648064?s=20
2m block buyer and 4m buyer loading up today
Nicely cashed up
News due on several fronts
Total next to us in South Africa
Surrounded by Exxon in Namibia
Drill-ready in Cameroon
Close to placing price
Warrants at 0.65
Pretty much bottom of the chart
MCAP £6m
Bought this afternoon and expecting strong move soon
Have a good weekend all
on AIM most people like buying when sentiment is high, all the way up the spike and some at the top!.. then get negged and sell on the way down the spike. Savvy folks load up when it is quiet, before sentiment builds, for SGS P2 results in a couple of months!.. and get to enjoy any other investment news from VELA in the meantime
smittty12 - never put your hard earned cash into something based on what people on the internet say, read through all the RNSs since James Normand was appointed to the board and take a look at the movement of his other company AAA in 2020. Good luck mate
Covid-19 Trial Update - 04-01-21
Approval Received to Begin Recruiting in Czech Republic and Romania
The ARCADIA clinical trial is a randomised, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with either Type 1 or Type 2 diabetes and admitted to hospital with COVID-19. The trial, which is sponsored by the UK charity St George Street, has successfully recruited 50 of the planned 150 patients across 11 UK hospital sites over the past 3 months. To help ensure timely completion of study enrolment, the ARCADIA trial is now expanding with the addition of approximately 23 new hospital sites over the coming weeks. In addition to 4 new sites in the UK, up to 19 sites are to be opened in Czech Republic and Romania. Regulatory and ethics committee approval for both new countries was received at the end of December 2020 and the first patients from Czech Republic and Romania are expected to be recruited to ARCADIA before the end of January 2021.
Both Czech Republic and Romania have a high prevalence of diabetes (10.2% and 8.8% of the population having diabetes respectively), this compares with around 6.5% of people in the UK. In addition, both countries have regularly reported over 100 deaths from COVID-19 per day throughout December, indicating a high unmet clinical need.
The decision and rapid action to obtain approval in Romania and Czech Republic is testament to the strength of the St George Street team and its collaborative relationships with its development partners. St George Street is delighted to have received such rapid regulatory approval in the two new countries and looks forward to collaborating closely with the investigational teams in both countries.
The mechanism of actions of AZD1656, both blood glucose lowering and potential immunomodulatory action, are independent of viral mutations. AZD1656 activates glucokinase, which is expected to increase the migration of T regulatory cells in addition to reducing blood glucose. Reducing hyperglycaemia (high blood glucose) is increasingly seen to be important to improve outcomes in people with diabetes and COVID-19. Migration of regulatory T cells is expected to dampen down the hyperinflammation seen in the lungs for instance, that results in severe COVID-19.
Dave Tapolczay, CEO of St George Street said ‘I am delighted with the progress of the ARCADIA trial so far in the UK and through adding an additional 23 hospital sites we expect to see a significant impact on patient recruitment of the trial. Credit must go to the team in obtaining regulatory approval so quickly in Czech Republic and Romania. As a society we will need many solutions to battle the surging pandemic and I am proud that here at St George Street we are playing our part in helping to find those solutions.’
...specific, as it is activating cells within our own body. This gives the treatment an advantage over many other treatments, and potentially it could be used in other virally induced respiratory diseases including other mutations of coronavirus, MERS and pneumonia. This gives AZD1656 longevity as a treatment beyond the current pandemic. AZD1656 is an orally available tablet that is stable at room temperature, making it suitable for use around the world. Furthermore, should the trial be successful, we expect to agree a commercial deal with a partner almost immediately."
The ARCADIA clinical trial is progressing very well, having recruited its first patient at the end of September. As of 13th December, 47 patients had been enrolled in the trial across 9 of our 11 UK hospital sites currently contracted. There are 4 further hospital sites being initiated week commencing 14th December to bolster recruitment. The current sites are spread throughout England with 5 of them in London and the South East. The trial aims to enrol 150 patients and the original plan was to recruit all of these from 15 sites in the UK. However, there was a dramatic fall-off in cases over the summer, for instance in the first two weeks of September there were no COVID-19 patients at all in some of our sites. This led SGS to the decision to evaluate the option of opening up sites in other countries. Ten additional countries were surveyed for suitability to open trial sites, taking into account the number of cases in the country (actual and forecast), the ability to manage and monitor a trial there, the appetite of the regulatory authorities, the presence of other clinical trials competing for patients, and the ability to deliver the drug there safely. As a result of that, SGS is at the final stages of initiating new trial sites in Romania and the Czech Republic including negotiating contracts and gaining regulatory approval. Additionally, the enrolment period of the trial has been extended so that patients can be accepted onto the trial until the end of February. At that time, or before if recruitment in the new countries goes quickly, all patients will have been dosed and the data collected in the trial will be locked down for a month while it is independently assessed and a report published.
The trial is completely randomised and double-blinded with a placebo arm, meaning that no clear data can be seen until the report is published. We note however that the drug is well tolerated with no safety concerns raised in previous trials of over 960 patients. The Chief Investigator in the trial is Dr Kieran McCafferty, specialist in diabetic nephrology at Barts NHS Trust and Queen Mary University.
Dave Tapolczay, CEO of SGS said "We are delighted with the progress of the ARCADIA trial. Obviously the news that we will shortly have vaccines available is very welcome, but it doesn't remove the need for treatments for COVID-19, especially for those with underlying conditions such as diabetes. In some cases, the vaccines will not be suitable for people with those conditions, in other cases the vaccine may not be 100% effective. Add to this the fact that uptake and supply of the vaccine may not be optimal, and it is highly likely that treatments will be needed for many years to come. Nobody should assume there will be only one way out of this pandemic. Certainly, big pharma companies want to offer a full suite of products for any disease area whether vaccine, prophylaxis, therapeutic, and for recovery. Unlike many other treatments AZD1656 is not virus